Screening panels evaluating GI biomarkers are recommended for diagnosis.

• A. Sometimes
• B. Always recommended
• C. False, not recommended
• D. True

Answer: (C)

The key idea is that GI biomarker panels are not definitive diagnostic tools. They can reflect inflammation, mucosal involvement, or barrier dysfunction, but they are not specific enough to pinpoint a particular disease. Because many conditions—such as infections, medications (like NSAIDs), colorectal neoplasia, and even functional disorders—can elevate or alter biomarker levels, a positive panel cannot confirm a specific diagnosis on its own.

These panels are best used as adjuncts to guide decision-making rather than replace definitive testing. For example, a biomarker indicating intestinal inflammation may prompt further workup (endoscopy with biopsy, imaging, targeted labs) when organic disease is suspected, but it cannot by itself distinguish between Crohn’s disease, ulcerative colitis, celiac disease, or other etiologies. They can help differentiate organic disease from functional disorders and are useful for monitoring activity or response to therapy in known inflammatory conditions, not for initial diagnosis.

So, relying on screening panels to diagnose GI disease is not recommended; they serve as helpful tools to inform and narrow the diagnostic process, not as stand-alone diagnostic tests.